摘要
目的研究尿激酶型纤溶酶原激活剂受体(uPAR)在人类表皮生长因子受体-2(HER-2)阳性乳腺癌中的作用及治疗前景。方法通过查询Pubmed,检索HER-2阳性乳腺癌中关于uPAR的研究,综合分析uPAR的作用。结果 uPAR在HER-2阳性乳腺癌中发挥十分重要的作用,利用抗uPAR单体或uPAR结合抑制剂可以抑制乳腺癌细胞的生长、侵袭和转移。结论 uPAR是乳腺癌的有效靶点之一,为HER-2阳性乳腺癌的治疗提供了新的突破口。
Objective Investigate the effect and treatment prospects of urokinase-type plasminogen activator receptor（uPAR）in human epidermal growth factor receptor-2（HER-2） positive breast cancer.Method Aricals related effect of uPAR in HER-2 positive breast caner were retrieved through Pubmed,and the role of uPAR was reviewed.Results uPAR played a very important role in the HER-2 positive breast cancer,anti-uPAR monomer or uPAR binding inhibitors could inhibit the growth,invasion and metastasis of breast cancer cells.Conclusion uPAR is one of the effective target for breast cancer,and it provides a new breakthrough in the treatment of HER-2 positive breast cancer.
出处
《中国普外基础与临床杂志》
CAS
2012年第10期1143-1146,共4页
Chinese Journal of Bases and Clinics In General Surgery
